188 related articles for article (PubMed ID: 19517218)
41. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
Durrieu L; Gregoire-Gauthier J; Dieng MM; Fontaine F; le Deist F; Haddad E
Cytotherapy; 2012 Nov; 14(10):1245-57. PubMed ID: 22974386
[TBL] [Abstract][Full Text] [Related]
42. Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells.
Wang Y; Dai H; Li H; Lv H; Wang T; Fu X; Han W
Clin Dev Immunol; 2011; 2011():621414. PubMed ID: 21455282
[TBL] [Abstract][Full Text] [Related]
43. Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor.
Turatti F; Figini M; Alberti P; Willemsen RA; Canevari S; Mezzanzanica D
J Gene Med; 2005 Feb; 7(2):158-70. PubMed ID: 15538730
[TBL] [Abstract][Full Text] [Related]
44. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway.
Iudicone P; Fioravanti D; Cicchetti E; Zizzari IG; Pandolfi A; Scocchera R; Fazzina R; Pierelli L
Hum Immunol; 2016 Dec; 77(12):1239-1247. PubMed ID: 27615504
[TBL] [Abstract][Full Text] [Related]
46. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo.
Wang FS; Liu MX; Zhang B; Shi M; Lei ZY; Sun WB; Du QY; Chen JM
World J Gastroenterol; 2002 Jun; 8(3):464-8. PubMed ID: 12046071
[TBL] [Abstract][Full Text] [Related]
47. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
Huang J; Li C; Wang Y; Lv H; Guo Y; Dai H; Wicha MS; Chang AE; Li Q
Clin Immunol; 2013 Oct; 149(1):156-68. PubMed ID: 23994769
[TBL] [Abstract][Full Text] [Related]
48. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells.
Verneris MR; Arshi A; Edinger M; Kornacker M; Natkunam Y; Karimi M; Cao YA; Marina N; Contag CH; Negrin RS
Clin Cancer Res; 2005 Jun; 11(12):4561-70. PubMed ID: 15958642
[TBL] [Abstract][Full Text] [Related]
49. [Autologous CIK cell infusion promotes amplification ability of CD3⁺ CD56⁺ cells when re-preparation from patients with malignant tumors].
Yu H; Sun Y; Lin D; Li C; Chen W; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):748-53, 758. PubMed ID: 25001943
[TBL] [Abstract][Full Text] [Related]
50. [Therapy of relapsed or refractory non-Hodgkin's lymphoma by antigen specific dendritic cells-activated lymphocytes].
Sun Y; Chen J; Cai P; Hu YH; Zhong GC; Feng HZ; Min M; Li S; Zhang C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):219-23. PubMed ID: 20137151
[TBL] [Abstract][Full Text] [Related]
51. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
52. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.
Dalla Pietà A; Cappuzzello E; Palmerini P; Ventura A; Visentin A; Astori G; Chieregato K; Mozzo V; Perbellini O; Tisi MC; Trentin L; Visco C; Ruggeri M; Sommaggio R; Rosato A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272306
[TBL] [Abstract][Full Text] [Related]
53. Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells signaled through STAT-3 and STAT5b pathways.
Rajbhandary S; Zhao MF; Zhao N; Lu WY; Zhu HB; Xiao X; Deng Q; Li YM
Asian Pac J Cancer Prev; 2013; 14(10):5825-31. PubMed ID: 24289584
[TBL] [Abstract][Full Text] [Related]
54. Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion.
Liu J; Wang L; Wang Y; Zhang W; Cao Y
PLoS One; 2017; 12(4):e0175704. PubMed ID: 28426690
[TBL] [Abstract][Full Text] [Related]
55. [Induction of dendritic cells from intra-operative lost blood and their effects on CIK against liver cancer cells in vitro].
DU Z; Zhao XL; Gao YT; Wu CX; Wang YJ; Zhu ZY; Sun Q; Fang SC
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):759-63. PubMed ID: 19173806
[TBL] [Abstract][Full Text] [Related]
56. Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors.
Hu L; Cao D; Li Y; He Y; Guo K
Cancer Biol Ther; 2012 May; 13(7):516-26. PubMed ID: 22406996
[TBL] [Abstract][Full Text] [Related]
57. Dendritic Cell Immunotherapy Combined with Cytokine-Induced Killer Cells Effectively Suppresses Established Hepatocellular Carcinomas in Mice.
Jung NC; Lee JH; Choi HJ; Hwang SU; Song JY; Seo HG; Choi J; Jung SY; Han SG; Lim DS
Immunol Invest; 2016 Aug; 45(6):553-65. PubMed ID: 27410037
[TBL] [Abstract][Full Text] [Related]
58. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
[TBL] [Abstract][Full Text] [Related]
59. Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood.
Zhang Z; Zhao X; Zhang T; Wang L; Yang L; Huang L; Li F; Liu J; Yue D; Wang F; Li J; Guan F; Xu Y; Zhang B; Zhang Y
Cytotherapy; 2015 Jan; 17(1):86-97. PubMed ID: 25457278
[TBL] [Abstract][Full Text] [Related]
60. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
Zhu BQ; Ju SW; Shu YQ
Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
